BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
BioMS Medical Corp. announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The trial, named MAESTRO-03, includes approximately 510 patients, and is being conducted at 68 trial sites in the U.S.
"We have had great success in recruiting patients into the trial, which is a testament to the promise of our approach and the efforts of our investigators," said Mr. Kevin Giese, President and CEO. "Since initiating this trial in June 2007 we have been delighted by the enthusiasm of the patients and clinical groups participating across the U.S."
MBP8298 (dirucotide) is currently being developed in three late-stage clinical trials:
1. MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS (SPMS) patients in Canada and Europe.
2. MAESTRO-03: A pivotal phase III trial for SPMS patients in the United States.
3. MINDSET-01: A phase II trial for relapsing-remitting MS (RRMS) patients in Europe.
Weitere News aus dem Ressort Forschung & Entwicklung
Holen Sie sich die Life-Science-Branche in Ihren Posteingang
Ab sofort nichts mehr verpassen: Unser Newsletter für Biotechnologie, Pharma und Life Sciences bringt Sie jeden Dienstag und Donnerstag auf den neuesten Stand. Aktuelle Branchen-News, Produkt-Highlights und Innovationen - kompakt und verständlich in Ihrem Posteingang. Von uns recherchiert, damit Sie es nicht tun müssen.
